Objective: An efficient anaerobic culture system, the InPouch TVTM test, was used to determine the susceptibility of Trichomonas vaginalis to metronidazole. Glacial acetic acid was employed as a solvent for metronidazole. Methods: T vaginalis isolates were cultured from 16 symptomatic female patients. The 1 1 who responded to oral metronidazole, 250 mg tid for 7 days, were considered as having sensitive trichomonads; the 5 who remained infected after treatment were considered to have resistant organisms. All isolates were cultured for minimum lethal concentrations (MLC). Metronidazole was added to a series of pouches; two-fold dilution of the most concentrated was 50 jug/ml and the least was 044ug/ml. The inoculum of viable trichomonads was 1 x 105/ml in each pouch. Pouches were incubated at 37°C for 48 h, examined microscopically for motile trichomonads, and then 0.5 ml was subcultured to drug free pouches. After 5 days incubation at 37°C, each subculture and culture were examined microscopically for viable trichomonads. Results: Eleven isolates of T vaginalis from patients responding to metronidazole treatment had MLC between 0.4 to 3-1 pg/ml. The MLC from the 5 treatment failure patients were between 12.5 to 50 jg/ml. Conclusions: For the 16 patients in this study, the MLC values determined with the InPouch TVJ\M test differentiated between infection caused by metronidazole sensitive and resistant trichomonads. The mean MLC of clinically resistant isolates was approximately eleven fold higher than the mean MLC of clinically sensitive isolates (15 ,ug/ml vs 1. 32 jug/ml). There was a significant difference between clinically resistant and sensitive isolates (t = 5.47, p < 0.0005). This study suggests that the InPouch TVrM test could be used for distinguishing between metronidazole resistant and sensitive isolates. (Genitourin Med 1996;72:132-135) 
Introduction
Metronidazole (flagyl; l-hydroxyethyl-2-methyl-5-nitroimidazole) is In the current study the stock metronidazole solution (100 mg/ml) was prepared with GAA. After dilution with NS, the concentration of GAA in the most concentrated metronidazole (100 jug/ml) solution used in the MLC determination was 0.42 mM HOAc. This was much less than the 6.5 mM which inhibited the growth of T vaginalis in the pouch. The MLCs of clinically sensitive isolates were from 0 4,ug/ml to 3 1 ug/ml and that of clinically resistant isolates were between 6.25 ,ug/ml and 25 ug/ml (fig 2) . The mean MLC of clinically resistant isolates was about eleven fold higher than the mean MLC of clinically sensitive isolates. The difference was significant (t = 5.47, p < 0.0005, table 3).
There were differences in the PVO for clinically sensitive and resistant T vaginalis after exposure to 12.5,g/ml, 25,g/ml, and 37. 5 ,ug/ml of metronidazole for as little as 15 min.
At 12.5 pg/ml the PVO of the clinically resistant isolate was 100% and that of the clinically sensitive isolate was 90% (fig 3) . The PVOs of the clinically resistant isolate in the pouches containing 25,g/ml and 375 5,g/ml were 100% and 98% respectively. But Lossick et all' reported that the anaerobic mean MLC of resistant isolates was about three-fold higher than that observed in nonresistant isolates (5.0 ,g/ml vs 1.6 pg/ml). In the current study, the mean MLC of the clinically resistant isolates was about eleven fold higher than the mean of the clinically sensitive isolates (15 pg/ml vs 1.3 ,g/ml). This difference was significant (t = 5.47, p < 0.0005).
In this evaluation the InPouch TVTM test provided an improved environment for distinguishing between resistant and sensitive T vaginalis. This suggests that the pouch test containing 3.1 jg/ml metronidazole differentiates between trichomonads that are either sensitive or resistant. T vaginalis remaining viable in pouches containing more than 3.1 jug/ml of , InL.metronidazole would be considered resistant. have been attributed to non-compliance in taking the drug as prescribed, limited absorpdon from the gastro-intestinal tract, inadequate concentrations in the vagina, and degradation by vaginal microbial flora.67 In a study of 11 patients, who were repeated treatment failures to oral metronidazole, (3 dosage levels during a 14-17 day period), high pressure liquid chromatographic analyses indicated that even at the low dosages, metronidazole and its metabolite were present in the expected concentrations both in plasma and the vagina.8 Therefore, treatment failure of these patients was not due to any of the previously suggested causes. The current study confirmed the resistance of some isolates of T vaginalis to metronidazole.
Metronidazole resistance has been evaluated employing a variety of procedures. A
